The Patent Finder

Sarepta Therapeutics, Inc.

106 patents currently held · Updated Nov 20, 2026
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Avi Biopharma, Inc. (to 2013)

36
Ending by 2030
Nov 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Dec 13 to 30, 2026 · next Dec 13
  • 3 fees due Jan 2 to 30, 2027 · next Jan 2
  • 1 fee due Feb 22, 2027
    The maintenance fee for Peptide Oligonucleotide Conjugates (US 11,732,259) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 1 fee due Apr 20, 2027
    The maintenance fee for Peptide Oligonucleotide Conjugates (US 9,161,948) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
  • 1 fee due May 26, 2027
    The maintenance fee for Peptide Oligonucleotide Conjugates (US 10,487,326) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
  • 1 fee due Jun 22, 2027
    The maintenance fee for Exon skipping compositions for treating muscular dystrophy (US 9,217,148) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
  • 2 fees due Jul 12 to 19, 2027 · next Jul 12
  • 1 fee due Aug 27, 2027
    The maintenance fee for Antisense-induced exon exclusion in type VII collagen (US 11,911,403) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 4 fees due Sep 3 to 19, 2027 · next Sep 3

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 22, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,030,291Antisense antiviral compounds and methods for treating a filovirus infection
In force
 · USPTO record
In forceUSPTO record
US 8,030,292Antisense antiviral compounds and methods for treating a filovirus infection
In force
 · USPTO record
In forceUSPTO record
US 8,067,571Antibacterial antisense oligonucleotide and method
In force
 · USPTO record
In forceUSPTO record
US 8,168,604Antisense antiviral compounds and methods for treating a filovirus infection
In force
 · USPTO record
In forceUSPTO record
US 7,582,615Antisense Antiviral Compound and Method for Treating Arenavirus Infection
In force
 · High confidence
In forceHigh confidence
US 8,053,420Peptide conjugated, inosine-substituted antisense oligomer compound and method
In force
 · USPTO record
In forceUSPTO record
US 7,790,694Antisense antibacterial method and compound
In force
 · USPTO record
In forceUSPTO record
US 8,536,147Antibacterial antisense oligonucleotide and method
In force
 · USPTO record
In forceUSPTO record
US 8,759,307Oligonucleotide compound and method for treating nidovirus infections
In force
 · USPTO record
In forceUSPTO record
US 9,161,948Peptide Oligonucleotide Conjugates
In force
 · Medium confidence
In forceMedium confidence
10 of 106 patents shown.
Pro members see all 106.
Pro members: see all 106 patents
Also on record, not counted in the 106: 6 patents in force now held by others · 23 lapsed for an unpaid fee · 28 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

32 pending · 19 abandoned · 58 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited